Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

(2019) Andrew H. Wei et al.   JOURNAL OF CLINICAL ONCOLOGY

Why are hypomethylating agents or low-dose cytarabine and venetoclax so effective?

(2019) Daniel A. Pollyea et al.   CURRENT OPINION IN HEMATOLOGY

Venetoclax-based Therapies for Acute Myeloid Leukemia

(2019) Veronica A. Guerra et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

FDA Approval Summary: Glasdegib for newly-diagnosed acute myeloid leukemia

(2019) Kelly J. Norsworthy et al.   CLINICAL CANCER RESEARCH

Unfolded Protein Response (UPR) in Survival, Dormancy, Immunosuppression, Metastasis, and Treatments of Cancer Cells

(2019) Sheng-Kai Hsu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Glasdegib with Low-Dose Cytarabine - A New Upfront Option for the Vulnerable AML Patient

(2019) Amir T Fathi   CLINICAL CANCER RESEARCH

The molecular mechanisms of chemoresistance in cancers

(2017) Hua-Chuan Zheng   Oncotarget

Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma

(2016) Hsiao-Hui Lin et al.   CANCER LETTERS

Wnt signaling and cellular metabolism in osteoblasts

(2016) Courtney M. Karner et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Drugging the unfolded protein response in acute leukemias

(2015) Behzad Kharabi Masouleh et al.   Journal of Hematology & Oncology

Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia

(2014) Smita Dandekar et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells

(2014) W Fiskus et al.   LEUKEMIA

Wnt pathway contributes to the protection by bone marrow stromal cells of acute lymphoblastic leukemia cells and is a potential therapeutic target

(2013) Yang Yang et al.   CANCER LETTERS

Wnt Signaling in Normal and Malignant Hematopoiesis

(2013) W. Lento et al.   Cold Spring Harbor Perspectives in Biology

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

(2011) Ethan Basch et al.   JOURNAL OF CLINICAL ONCOLOGY

The Wnt/ -Catenin Pathway Is Required for the Development of Leukemia Stem Cells in AML

(2010) Y. Wang et al.   SCIENCE

Dose Escalation Methods in Phase I Cancer Clinical Trials

(2009) Christophe Le Tourneau et al.   JNCI-Journal of the National Cancer Institute

Evidence that Fold-Change, and Not Absolute Level, of β-Catenin Dictates Wnt Signaling

(2009) Lea Goentoro et al.   MOLECULAR CELL

Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome

(2008) Jinglan Xu et al.   BRITISH JOURNAL OF HAEMATOLOGY

Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells

(2008) Katharina Salome Minke et al.   EUROPEAN JOURNAL OF HAEMATOLOGY